Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anxiety AND Social Phobia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Anxiety AND Social Phobia. Displaying page 1 of 1.
    EudraCT Number: 2014-004475-23 Sponsor Protocol Number: 47410 Start Date*: 2016-10-05
    Sponsor Name:Radboud University Nijmegen
    Full Title: Enhancement of exposure therapy for social anxiety disorder with testosterone: A randomized clinical trial
    Medical condition: Social Anxiety Disorder (Social Phobia)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10041250 Social phobia PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015538-30 Sponsor Protocol Number: OXTsozphob Start Date*: 2010-04-21
    Sponsor Name:Rheinisch-Westfälisch Technische Hochschule Aachen
    Full Title: Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control
    Medical condition: The effect of oxytocin is investigated in social processing of social phobic patient and healthy controls
    Disease: Version SOC Term Classification Code Term Level
    12.0 10041250 Social phobia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005366-30 Sponsor Protocol Number: Hovatta_Erkko_001 Start Date*: 2016-09-05
    Sponsor Name:University of Helsinki
    Full Title: RESOLVING THE NEUROBIOLOGICAL MECHANISMS OF ANXIETY DISORDERS – BRAIN IMAGING SUB-STUDY
    Medical condition: Social Anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10041242 Social anxiety disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023007-10 Sponsor Protocol Number: TF2010 Start Date*: 2011-03-22
    Sponsor Name:Uppsala university
    Full Title: A neuroscience perspective on anxiety proneness - Sex differences, monoaminergic pathways and treatment response
    Medical condition: Men and women diagnosed with DSM-IV social phobia (social anxiety disorder)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10041242 Social anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003597-10 Sponsor Protocol Number: CRH103390 Start Date*: 2006-11-04
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
    Medical condition: Social Anxiety Disorder (SocAD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041242 Social anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004094-17 Sponsor Protocol Number: 40-41200-98-9269 Start Date*: 2015-11-03
    Sponsor Name:Universiteit Utrecht
    Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias.
    Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068299 Fear symptoms and phobic disorders (incl social phobia) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-001894-24 Sponsor Protocol Number: NKP103401 Start Date*: 2004-11-04
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients...
    Medical condition: Subjects with Social Anxiety Disorder (SAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000954-22 Sponsor Protocol Number: CI-1008-100 Start Date*: 2004-09-23
    Sponsor Name:Pfizer Global Research & Development
    Full Title: A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-001955-11 Sponsor Protocol Number: AP105162012 Start Date*: 2013-12-26
    Sponsor Name:Psicofundación. Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicología
    Full Title: A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial
    Medical condition: Emotional disorders specified as anxiety disorders (e.g., panic disorder, generalized anxiety disorder, social phobia, specific phobia), mood disorders (e.g., major depressive disorder, dysthymia),...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004780-34 Sponsor Protocol Number: A7571001 Start Date*: 2006-04-18
    Sponsor Name:Pfizer Ltd, Sandwich, UK
    Full Title: An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients w...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025454 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021788-33 Sponsor Protocol Number: A3051075 Start Date*: 2011-07-13
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 4, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VARENICLINE COMPARED TO PLACEBO FOR SMOKING CESSATION THROUGH REDUCTION
    Medical condition: Smoking Cessation
    Disease: Version SOC Term Classification Code Term Level
    15.0 10041244 - Social circumstances 10008374 Cessation of smoking LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001718-26 Sponsor Protocol Number: DFI10560 Start Date*: 2010-05-07
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of t...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10025453 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022914-15 Sponsor Protocol Number: A3051123 Start Date*: 2012-03-01
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD...
    Medical condition: Nicotine Addiction with the desire to quit smoking
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053325 Smoking cessation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:06:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA